These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 26314715

  • 21. Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.
    Yang CC, Tsai WL, Su WW, Huang CF, Cheng PN, Lo CC, Tseng KC, Mo LR, Wang CH, Hsu SJ, Lai HC, Su CW, Liu CJ, Peng CY, Yu ML.
    PLoS One; 2015; 10(9):e0137852. PubMed ID: 26368130
    [Abstract] [Full Text] [Related]

  • 22. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team.
    N Engl J Med; 2011 Jun 23; 364(25):2405-16. PubMed ID: 21696307
    [Abstract] [Full Text] [Related]

  • 23. Telaprevir for retreatment of HCV infection.
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, REALIZE Study Team.
    N Engl J Med; 2011 Jun 23; 364(25):2417-28. PubMed ID: 21696308
    [Abstract] [Full Text] [Related]

  • 24. Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.
    Cento V, Di Paolo D, Di Carlo D, Micheli V, Tontodonati M, De Leonardis F, Aragri M, Antonucci FP, Di Maio VC, Mancon A, Lenci I, Manunta A, Taliani G, Di Biagio A, Nicolini LA, Nosotti L, Sarrecchia C, Siciliano M, Landonio S, Pellicelli A, Gasbarrini A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F.
    Dig Liver Dis; 2015 Feb 23; 47(2):157-63. PubMed ID: 25544656
    [Abstract] [Full Text] [Related]

  • 25. Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?
    Nicolini LA, Menzaghi B, Ricci E, Martinelli C, Magni C, Maggi P, Celesia BM, Parruti G, Babudieri S, Bonfanti P, Falasca K, Vichi F, De Socio GV, Salomoni E, Di Biagio A, Quirino T.
    Eur J Gastroenterol Hepatol; 2016 Jan 23; 28(1):37-41. PubMed ID: 26460621
    [Abstract] [Full Text] [Related]

  • 26. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
    Salmon D, Bani-Sadr F, Gilbert C, Rosenthal E, Valantin MA, Simon A, Neau D, Morlat P, Loko MA, Wittkop L, Dabis F, ANRS CO13HEPAVIH study group.
    J Clin Virol; 2015 Dec 23; 73():32-35. PubMed ID: 26528903
    [Abstract] [Full Text] [Related]

  • 27. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.
    Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF.
    PLoS One; 2014 Dec 23; 9(4):e94542. PubMed ID: 24728219
    [Abstract] [Full Text] [Related]

  • 28. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.
    Clin Gastroenterol Hepatol; 2013 Nov 23; 11(11):1503-10. PubMed ID: 23707354
    [Abstract] [Full Text] [Related]

  • 29. Boceprevir for previously treated chronic HCV genotype 1 infection.
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, HCV RESPOND-2 Investigators.
    N Engl J Med; 2011 Mar 31; 364(13):1207-17. PubMed ID: 21449784
    [Abstract] [Full Text] [Related]

  • 30. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.
    Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M.
    Gastroenterology; 2011 Sep 31; 141(3):881-889.e1. PubMed ID: 21699786
    [Abstract] [Full Text] [Related]

  • 31. [Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
    Macías J, Rivero A.
    Enferm Infecc Microbiol Clin; 2013 Jul 31; 31 Suppl 3():33-6. PubMed ID: 24063901
    [Abstract] [Full Text] [Related]

  • 32. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M.
    Lancet; 2014 Aug 02; 384(9941):403-13. PubMed ID: 24907225
    [Abstract] [Full Text] [Related]

  • 33. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
    Sitole M, Silva M, Spooner L, Comee MK, Malloy M.
    Clin Ther; 2013 Feb 02; 35(2):190-7. PubMed ID: 23369368
    [Abstract] [Full Text] [Related]

  • 34. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.
    Cooper C, Lester R, Thorlund K, Druyts E, El Khoury AC, Yaya S, Mills EJ.
    QJM; 2013 Feb 02; 106(2):153-63. PubMed ID: 23159839
    [Abstract] [Full Text] [Related]

  • 35. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P, Reddy KR.
    Antivir Ther; 2011 Feb 02; 16(8):1187-201. PubMed ID: 22155901
    [Abstract] [Full Text] [Related]

  • 36. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.
    Clin Gastroenterol Hepatol; 2013 Aug 02; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [Abstract] [Full Text] [Related]

  • 37. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V, Ciancio A, Petta S, Karampatou A, Turco L, Strona S, Critelli R, Todesca P, Cerami C, Sagnelli C, Rizzetto M, Cammà C, Villa E.
    World J Gastroenterol; 2014 Nov 28; 20(44):16726-33. PubMed ID: 25469044
    [Abstract] [Full Text] [Related]

  • 38. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection.
    Martel-Laferrière V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, Schiano T, Sulkowski M, Dieterich D, Branch A.
    HIV Med; 2014 Feb 28; 15(2):108-15. PubMed ID: 24025147
    [Abstract] [Full Text] [Related]

  • 39. Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection.
    Wehmeyer MH, Eißing F, Jordan S, Röder C, Hennigs A, Degen O, Hüfner A, Hertling S, Schmiedel S, Sterneck M, van Lunzen J, Lohse AW, Schulze zur Wiesch J, Lüth S.
    BMC Gastroenterol; 2014 May 05; 14():87. PubMed ID: 24884400
    [Abstract] [Full Text] [Related]

  • 40. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
    Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourlière M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM, ANRS HC27 BOCEPREVIH Study Group.
    HIV Clin Trials; 2016 Mar 05; 17(2):63-71. PubMed ID: 27077673
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.